ClinicalTrials.gg
RecruitingNCT06133803Updated Feb 21, 2024

Lovenox With Aspirin in Thawed Blastocyst Transfer

A Phase 4 interventional study of Lovenox and Aspirin in Infertility, Female, sponsored by Fertility Center of Las Vegas. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Fertility Center of Las Vegas · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 25 under way, none of them phase 3. Infertility, Female · United States.

Planned enrollment
13th of 47
130 · median 50
Started
2024
with 5 others
Phase 4
6 of 65
3 open now
Primary completion
2024-12
later than 5 of 24 live
Registered
50th of 65
by date
Lead sponsor
3 of 65
Fertility Center of Las Vegas

Among the 65 studies in Infertility, Female with a site in United States, this one is the 13th largest by planned enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2024, is one of 6 in phase 4, reaches primary completion later than 5 of the 24 other live ones, and was the 50th registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 42 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Infertility, Female with a site in United States, or all of them as a file.
02

Study summary

This prospective randomized trial will compare outcomes in patients receiving aspirin in combination with a low-molecular weight heparin and those under this center's standard protocol receiving neither medication, in order to determine if these medications may improve success rates.

Read the detailed description

This prospective randomized trial will compare outcomes in patients receiving aspirin (81mg daily) in combination with a low-molecular weight heparin (LMWH) (enoxaparin (Lovenox®), 40mg daily subcutaneous injection) and those under this center's standard protocol receiving neither medication, in order to determine if these medications may improve success rates.

03

Conditions studied

  • Infertility, Female

Browse trials for

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patient 18-42 years of age with frozen embryos or oocytes seeking embryo transfer.
  2. Use of pre-implantation genetically tested (PGT) blastocysts is allowed but not required.
  3. Use of donated embryos or embryos derived from donated eggs is allowed.
  4. Prior history of successful, failed, and/or canceled IVF cycles are allowed.

Exclusion criteria

Exclusion Criteria:

  1. Minor (age\<18 years).
  2. Currently pregnant.
  3. Unable to provide in English.
  4. Gestational carrier or "surrogate".
  5. Blastocysts frozen at another center (Oocytes frozen elsewhere is acceptable).
  6. Subject intending or having "natural cycle" thaw transfer with an active ovarian follicle present.
  7. Currently participating in any other research study.
  8. Subject already had an embryo transfer under this study.
  9. History of thrombocytopenia (reduced ), bleeding disorders, or routinely using anti-coagulant medication.
  10. to aspirin, heparin, or benzyl alcohol.
  11. Anyone for whom the physician assesses this protocol is inappropriate or unsafe.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Patients randomized to receive aspirin and Lovenox will begin taking one "low dose" 81mg aspirin and one 40mg injection of Lovenox daily, on the day of progesterone start.

    Drug: Lovenox · Drug: Aspirin · Procedure: Embryo transfer

  • Active comparator
    Control Arm

    This arm receives neither medication.

    Procedure: Embryo transfer

Interventions

  • A low-molecular-weight heparin, 40mg daily injection.

  • Aspirin 81mg daily tablet.

  • ProcedureEmbryo transfer

    Embryo transfer

06

What researchers measure

Primary outcomes

  1. Serum hCG level

    Serum hCG level

    Time frame: 5 days post transfer

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

Of 37 phase 4 interventional studies under Infertility, Female, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 18, 2023
StartActual
Jan 26, 2024
Primary completionEst.
Dec 15, 2024
CompletionEst.
Dec 15, 2024
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06133803
Lead sponsor
Fertility Center of Las Vegas
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Jan 26, 2024
Primary completion
Dec 15, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Feb 21, 2024

Study contacts

Shironda Anderson
Contact
shironda@fertilitycenterlv.com
702-254-1777
Bruce Shapiro, MD, PhD
principal investigator · Fertility Center of Las Vegas

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enoxaparin sodium · Aspirin

Start the discussion